Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. USO
3. CRNX
4. VRTX
5. SPY
6. LMT
7. WMT
8. CMPS
9. NVDA
10. RXST

Go back to Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs

December 7, 2021 6:39 AM EST

Goldman Sachs analyst Salveen Richter raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $28.00 (from $25.00) while maintaining a Neutral rating.

... More